Johns Hopkins University is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Johns Hopkins University (JHU), founded in 1876, is one of the world's leading research universities and a major center for neurodegenerative disease research. Located in Baltimore, Maryland, the university has been at the forefront of neuroscience research for over a century. The Johns Hopkins Alzheimer's Disease Research Center (ADRC), established in 1984, is one of the original NIH-funded Alzheimer's Disease Research Centers, and the Morris K. Udall Centers of Excellence for Parkinson's Disease Research represent cornerstone programs in understanding and treating these devastating disorders.
| Attribute |
Details |
| Full Name |
Johns Hopkins University |
| Location |
Baltimore, Maryland, USA |
| Type |
Private Research University |
| Founded |
1876 |
| Students |
~30,000 |
| Motto |
Veritas vos liberabit (The truth shall make you free) |
| Website |
jhu.edu |
Johns Hopkins University was founded in 1876 by Johns Hopkins, a philanthropist who envisioned a research university that would combine advanced scholarship with practical education. The university opened its medical school in 1893, and the School of Medicine quickly became one of the nation's leading medical institutions.
Johns Hopkins has been a pioneer in neuroscience research throughout its history. The Johns Hopkins Alzheimer's Disease Research Center was established in 1984 as one of the original NIH-funded ADRCs, and the institution has continued to lead in neurodegeneration research. The institution has produced numerous landmark discoveries in understanding Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
Founded in 1984, the Johns Hopkins ADRC is one of the original NIH-funded Alzheimer's Disease Research Centers. The center focuses on:
- Early Detection and Biomarkers - CSF, blood, and imaging biomarkers for preclinical AD
- Clinical Trials - Novel therapeutics including anti-amyloid, anti-tau, and novel mechanisms
- Neuroimaging Advances - Amyloid and tau PET, structural and functional MRI
- Genetic Risk Factors - APOE, TREM2, and novel genetic risk variants
- Neuropathology - Brain banking, Lewy body and Alzheimer's pathology studies
JHU houses a Udall Center of Excellence for Parkinson's Disease Research, focusing on:
- Alpha-synuclein Biology - Aggregation mechanisms, strain diversity, propagation
- LRRK2 Kinase Function - Pathogenic mutations, kinase inhibitors
- Dopaminergic Neuron Survival - Mechanisms of vulnerability and resilience
- Protein Degradation - Autophagy, ubiquitin-proteasome system
¶ Center for Neurodegeneration and Repair
This interdisciplinary center brings together researchers from neurology, neuroscience, psychiatry, and engineering:
- Protein Misfolding and Aggregation - Amyloid, tau, alpha-synuclein, TDP-43
- Neuroinflammation - Microglia, complement, peripheral immune interactions
- Neurovascular Dysfunction - Blood-brain barrier, cerebral blood flow
- Computational Neuroscience - Machine learning for biomarker discovery
A multidisciplinary center focused on:
- Cognitive Reserve - Building resilience to neurodegeneration
- Lifestyle Interventions - Exercise, diet, cognitive training
- Prevention Trials - Preclinical Alzheimer's intervention studies
Leading research in:
- Stem Cell Therapy - iPSC models of neurodegeneration
- Gene Therapy - AAV-delivered therapeutic proteins
- Regenerative Medicine - Cell replacement approaches
- Dr. Juan Troncoso - Director of the ADRC, expert in Lewy body pathology and aging, neuropathology
- Dr. John Gear - Parkinson's disease researcher, LRRK2 biology, protein aggregation
- Dr. Marilyn Albert - Cognitive neuroscience, early detection biomarkers, clinical trials
- Dr. Rebecca Gottesman - Vascular contributions to cognitive impairment, stroke and dementia
- Dr. Oliver S. John - Statistical genetics, GWAS, polygenic risk scores
- Dr. Jeffrey Rothstein - ALS researcher, TDP-43, glutamate excitotoxicity
- Dr. Philip Wong - Tau biology, protein aggregation mechanisms
- Dr. David Sullivan - Prion diseases, protein misfolding
- Dr. Guy M. McKhann - Alzheimer's disease clinical trials, cognitive assessment
- TREM2 variants: JHU researchers contributed to discovering TREM2 risk variants for Alzheimer's disease (Guerreiro et al., 2013)
- Lewy body pathology: Seminal work on the distribution and progression of Lewy bodies in Parkinson's disease (Troncoso et al.)
- Biomarker development: Pioneering CSF and plasma biomarker studies for AD and PD
- Neuroimaging advances: Development and validation of amyloid and tau PET imaging methods
- LRRK2 biology: Discovery of LRRK2 mutations in Parkinson's disease
- Tau propagation: Foundational work on tau oligomerization and spread
- Johns Hopkins School of Medicine - Research hospitals and laboratories
- Brain Resource Center - Brain banking, postmortem tissue
- MRI Imaging Center - 3T and 7T MRI scanners
- PET Imaging Facility - Amyloid, tau, and FDG PET
- Stem Cell Core - iPSC derivation and differentiation
- Clinical Trials Unit - Phase I-III clinical trials
- MD/PhD Program - Combined medical and research training
- PhD in Neuroscience - Program in Cellular and Molecular Medicine
- Postdoctoral Fellowships - NIH-funded training positions
- Neurology Residency - ACGME-accredited training
| Disease |
Research Intensity |
| Alzheimer's Disease |
Very High |
| Parkinson's Disease |
Very High |
| Lewy Body Dementia |
High |
| ALS |
High |
| Frontotemporal Dementia |
Moderate-High |
| Prion Diseases |
Moderate |
The study of Johns Hopkins University has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Troncoso JC, et al. (2008). Lewy body pathology in normal aging. Neurobiology of Aging.
- Singleton A, et al. (2003). α-Synuclein locus triplication causes Parkinson's disease. Science.
- Rebeck GW, et al. (2018). The role of APOE in Alzheimer's disease. JAMA Neurology.
- Moghekar A, et al. (2012). Cerebrospinal fluid biomarkers in Alzheimer's disease. Neurology.
- Guerreiro R, et al. (2013). TREM2 variants in Alzheimer's disease. New England Journal of Medicine.
- Chen-Plotkin AS, et al. (2018). LRRK2: a promising therapeutic target in Parkinson's disease. Nature Reviews Neurology.
- Alzheimer's Disease Research Center Annual Reports 2020-2024.